Abstract LB366: Fianlimab + cemiplimab in patients (pts) with advanced (adv) melanoma (Mel): Subgroup analyses by blinded independent central review (BICR)

Authors: Meredith McKean, Amy M. Weise, Kyriakos P. Papadopoulos, John Crown, Sajeve S. Thomas, Janice Mehnert, John M. Kaczmar, Kevin B. Kim, Nehal J. Lakhani, Melinda L. Yushak, Jayakumar Mani, Fang Fang, Shuquan Chen, Jingxiao Chen, Laura Brennan, JuAn Wang, Israel Lowy, Mark Salvati, Matthew G. Fury, Karl D. Lewis, Omid Hamid

Published: 2025-04-25

DOI: 10.1158/1538-7445.am2025-lb366

Source: Full article